[go: up one dir, main page]

CY1107323T1 - Αναστολεις πρωτεασωμικης δρασης για διεγepση τριχοφυϊας - Google Patents

Αναστολεις πρωτεασωμικης δρασης για διεγepση τριχοφυϊας

Info

Publication number
CY1107323T1
CY1107323T1 CY20071100174T CY071100174T CY1107323T1 CY 1107323 T1 CY1107323 T1 CY 1107323T1 CY 20071100174 T CY20071100174 T CY 20071100174T CY 071100174 T CY071100174 T CY 071100174T CY 1107323 T1 CY1107323 T1 CY 1107323T1
Authority
CY
Cyprus
Prior art keywords
hypothesis
protective action
hair
hair disease
compounds
Prior art date
Application number
CY20071100174T
Other languages
English (en)
Inventor
Gregory R Mundy
I Ross Garrett
G Rossini
Original Assignee
Osteoscreen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osteoscreen, Inc. filed Critical Osteoscreen, Inc.
Publication of CY1107323T1 publication Critical patent/CY1107323T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)

Abstract

Συνθέσεις που αναστέλλουν τη δράση του NF-κΒ ή τη δράση του πρωτεασώματος ή ευνοούν τον σχηματισμό οστών και την τριχοφυΐα και είναι κατά συνέπεια χρήσιμες στην θεραπεία της οστεοπόρωσης, της θραύσης ή ατέλειας των οστών, του πρωτογενούς ή δευτερογενούς υπερπαραθυροειδισμού, των περιοδοντικών ασθενειών ή ατελειών, της μεταστατικής ασθένειας των οστών, της οστεολυτικής ασθένειας των οστών, της μεταπλαστικής χειρουργικής, της μεταπροσθετικής χειρουργικής συνδέσμων, και της μετά οδοντικής εμφύτευσης. Επίσης διεγείρουν την παραγωγή τριχοθυλακίων και επομένως είναι χρήσιμες στην διέγερση τριχοφυΐας, συμπεριλαμβανομένης της πυκνότητας μαλλιών, σε οργανισμούς όπου αυτό είναι επιθυμητό.
CY20071100174T 1998-07-10 2007-02-09 Αναστολεις πρωτεασωμικης δρασης για διεγepση τριχοφυϊας CY1107323T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/113,947 US6462019B1 (en) 1998-07-10 1998-07-10 Inhibitors of proteasomal activity and production for stimulating bone growth
EP99933827A EP1096924B1 (en) 1998-07-10 1999-07-09 Inhibitors of proteasomal activity for stimulating hair growth

Publications (1)

Publication Number Publication Date
CY1107323T1 true CY1107323T1 (el) 2012-11-21

Family

ID=22352464

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100174T CY1107323T1 (el) 1998-07-10 2007-02-09 Αναστολεις πρωτεασωμικης δρασης για διεγepση τριχοφυϊας

Country Status (12)

Country Link
US (3) US6462019B1 (el)
EP (1) EP1096924B1 (el)
JP (2) JP2003522107A (el)
AT (1) ATE345785T1 (el)
AU (1) AU771297B2 (el)
CA (1) CA2337988C (el)
CY (1) CY1107323T1 (el)
DE (1) DE69934120T2 (el)
DK (1) DK1096924T3 (el)
ES (1) ES2273505T3 (el)
PT (1) PT1096924E (el)
WO (1) WO2000002548A2 (el)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462019B1 (en) * 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6838436B1 (en) * 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6492333B1 (en) 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US20090060988A1 (en) * 1999-10-05 2009-03-05 Kang Ting Nell-1 enhanced bone mineralization
US7884066B2 (en) * 1999-10-05 2011-02-08 The Regents Of The University Of California NELL-1 enhanced bone mineralization
US20060111313A1 (en) * 2002-09-13 2006-05-25 Kang Ting Nell-1 enhanced bone mineralization
US7687462B2 (en) * 1999-10-05 2010-03-30 The Regents Of The University Of California Composition for promoting cartilage formation or repair comprising a nell gene product and method of treating cartilage-related conditions using such composition
US7052856B2 (en) * 1999-10-05 2006-05-30 The Regents Of The University Of California NELL-1 enhanced bone mineralization
CA2385958A1 (en) * 1999-10-20 2001-04-26 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone and hair growth
WO2004103410A1 (en) 2002-06-06 2004-12-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods compositions and articles of manufacture for modulating bone growth
US7041309B2 (en) * 2002-06-13 2006-05-09 Neuropro Technologies, Inc. Spinal fusion using an HMG-CoA reductase inhibitor
EP1542682A4 (en) * 2002-07-18 2007-10-31 Univ Utah Res Found NEW HEMMER OF UBIQUITINE ISOPEPTIDASES
US7029006B2 (en) * 2002-08-29 2006-04-18 Canon Kabushiki Kaisha Sheet feeding apparatus and image forming apparatus
DE602004032107D1 (de) * 2003-02-07 2011-05-19 Univ California Nell-peptidexpressionssysteme und knochenbildende aktivität des nell-peptids
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
EP2329831A3 (en) 2003-11-05 2011-08-17 Osteoscreen, Inc. Stimulation of hair growth by Ginko biloba flavanoids
US7691607B2 (en) * 2004-02-09 2010-04-06 The Regents Of The University Of California Expression system of NELL peptide
US7232818B2 (en) * 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
US8129346B2 (en) 2004-04-15 2012-03-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
CA2565407A1 (en) 2004-05-10 2005-11-24 Proteolix, Inc. Compounds for enzyme inhibition
US20050256324A1 (en) * 2004-05-10 2005-11-17 Proteolix, Inc. Synthesis of amino acid keto-epoxides
FR2870739B1 (fr) * 2004-05-26 2008-05-16 Oreal Utilisation du lif en cosmetique et en dermatologie
US20060167106A1 (en) * 2004-11-19 2006-07-27 Mei Zhang Compounds acting at the centrosome
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7833968B2 (en) * 2005-02-16 2010-11-16 The Regents Of The University Of California Pharmaceutical compositions for treating or preventing bone conditions
KR101434522B1 (ko) * 2005-11-09 2014-08-26 오닉스 세라퓨틱스, 인크. 효소 저해를 위한 화합물
US7691852B2 (en) 2006-06-19 2010-04-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
US20100105762A1 (en) * 2007-02-16 2010-04-29 Ryuichi Morishita Therapeutic agent for periodontal disease and alveolar bone loss due to surgery
US7781650B2 (en) * 2007-04-30 2010-08-24 Monsanto Technology Llc Plants and seeds of corn variety CV202909
RS54847B2 (sr) 2007-10-04 2019-09-30 Onyx Therapeutics Inc Inhibitori kristalne peptid epoksi keton proteaze i sinteza aminokiselinskih keto-epoksida
JP5675629B2 (ja) 2008-10-21 2015-02-25 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンを用いた併用療法
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
WO2011087822A1 (en) 2009-12-22 2011-07-21 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
MA34133B1 (fr) 2010-03-01 2013-04-03 Onyx Therapeutics Inc Composes pour inhibiteurs de l'immunoproteasome
WO2011136905A2 (en) 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
US20110281256A1 (en) 2010-05-17 2011-11-17 Michael Glenn Davis Systems and Methods of Detecting and Demonstrating Hair Damage Via Evaluation of Protein Fragments
JP5737756B2 (ja) * 2011-07-06 2015-06-17 Ｎｅｃプラットフォームズ株式会社 通信装置およびパケット廃棄軽減方法
WO2013167927A1 (en) * 2012-05-11 2013-11-14 Biologix Hair Science Ltd. Formulation and method for treating hair loss
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
EP2874606B1 (en) * 2012-07-18 2019-03-06 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
SG10201913448UA (en) * 2013-03-15 2020-02-27 Human Biomolecular Res Institute Compounds and matrices for use in bone growth and repair
CN111514128A (zh) * 2020-04-30 2020-08-11 广州中医药大学第一附属医院 羟基红花黄色素a在制备治疗骨质疏松药物中的应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761471A (en) 1980-08-04 1988-08-02 The Regents Of The University Of California Bone morphogenetic protein composition
JPS60243008A (ja) * 1984-05-17 1985-12-03 Wakamoto Pharmaceut Co Ltd 発毛養毛剤
JPS6219513A (ja) * 1985-07-17 1987-01-28 Shiseido Co Ltd 養毛剤
WO1990011366A1 (en) 1989-03-28 1990-10-04 Genetics Institute, Inc. Osteoinductive compositions
ATE124863T1 (de) 1990-08-14 1995-07-15 Howmedica Knochenwachstumsstimulator.
JPH0597697A (ja) 1991-10-02 1993-04-20 Lion Corp 歯槽骨再生剤
WO1993020859A1 (en) 1992-04-20 1993-10-28 Board Of Regents Of The University Of Washington Sustained release compositions for delivery of growth factors
US5962301A (en) * 1992-06-12 1999-10-05 Massachusetts Institute Of Technology Relatedness of human interleukin-1β convertase gene to a C. elegans cell death gene, inhibitory portions of these genes and uses therefor
EP0672151A1 (en) * 1992-06-12 1995-09-20 Massachusetts Institute Of Technology Inhibitors of ced-3 and related proteins
US5280040A (en) 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
US5965530A (en) 1993-03-26 1999-10-12 Amgen Inc. Therapeutic uses of keratinocyte growth factor
US5840277A (en) 1993-03-30 1998-11-24 Charlotte Hospital Authority Treatment of chronic pulmonary inflammation
FI961697A7 (fi) 1993-10-21 1996-04-18 Merck & Co Inc 16-substituoidut-4-atsa-androstaani 5alfa-reduktaasi-isotsyymi-1-inhib iittorit
US5580854A (en) 1994-03-04 1996-12-03 Mount Sinai School Of Medicine Of The City University Of New York Substrate-related peptidyl-aldehyde inhibitors of the proteolytic activity of the multicatalytic proteinase complex
AU685619B2 (en) 1994-03-08 1998-01-22 Osteosa Inc. Use of fibroblast growth factors to stimulate bone growth
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) * 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
WO1996033268A1 (en) * 1995-04-21 1996-10-24 Merck & Co., Inc. Apopain
US5767152A (en) 1995-05-04 1998-06-16 Nielsen; Thor Bagger Composition and methods for stimulating hair growth
US6083690A (en) 1995-06-02 2000-07-04 Osteoscreen, Inc. Methods and compositions for identifying osteogenic agents
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
WO1997009315A1 (en) 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
PL327617A1 (en) 1995-10-23 1998-12-21 Zymogenetics Inc Compositions for and methods of treating osseous insufficiency
FR2741076B1 (fr) * 1995-11-15 1998-01-30 Rech De Pathologie Appliquee S Conjugues peptidiques derives des hormones thymiques, leur utilisation a titre de medicament et compositions les contenant
KR20000022040A (ko) 1996-06-20 2000-04-25 보오드 오브 리젠츠, 더 유니버시티 오브 텍사스 시스템 약학적 활성 제제를 제공하기 위한 화합물, 방법 및 그의 용도
AU4988997A (en) 1996-10-23 1998-05-15 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
AU729793B2 (en) 1996-12-13 2001-02-08 Zymogenetics Inc. Compositions and methods for stimulating bone growth
US6495532B1 (en) * 1997-03-19 2002-12-17 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
DE19716713A1 (de) 1997-04-21 1998-10-22 Paz Arzneimittelentwicklung Arzneimittel, enthaltend Ibuprofenthioester als Hemmer der Nf-kappaB abhängigen Bildung von Mediatoren von Entzündung und Schmerz
JPH11180873A (ja) 1997-12-22 1999-07-06 Kaken Shoyaku Kk ＮＦ−κＢ活性阻害剤
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6902721B1 (en) * 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) * 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6492333B1 (en) * 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors

Also Published As

Publication number Publication date
DE69934120D1 (de) 2007-01-04
CA2337988A1 (en) 2000-01-20
ES2273505T3 (es) 2007-05-01
DK1096924T3 (da) 2007-03-26
EP1096924B1 (en) 2006-11-22
WO2000002548A2 (en) 2000-01-20
PT1096924E (pt) 2007-02-28
US6410512B1 (en) 2002-06-25
US6958220B2 (en) 2005-10-25
US20020103127A1 (en) 2002-08-01
AU6310999A (en) 2000-02-01
EP1096924A1 (en) 2001-05-09
DE69934120T2 (de) 2007-10-11
US6462019B1 (en) 2002-10-08
WO2000002548A3 (en) 2003-04-17
JP4469780B2 (ja) 2010-05-26
JP2003522107A (ja) 2003-07-22
HK1035870A1 (en) 2001-12-14
JP2006089498A (ja) 2006-04-06
CA2337988C (en) 2011-04-26
ATE345785T1 (de) 2006-12-15
AU771297B2 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
CY1107323T1 (el) Αναστολεις πρωτεασωμικης δρασης για διεγepση τριχοφυϊας
EP1021179A4 (en) METHOD FOR PROMOTING HAIR GROWTH AND DEVELOPING THE HAIR SYSTEM
PT1399220E (pt) Dispositivo que estimula a actividade dos folículos de cabelo
BR0108977A (pt) Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina
DE3280344D1 (de) Verwendung von retinoiden und minoxidil (2,4-diamino-6-piperidino-pyrimidine-3-oxid) zur verbesserung des wachstums von menschlichem kopfhaar und zur behandlung bestimmter typen von alopecia.
CY1108778T1 (el) Μεθοδος αντιμετωπισης καρκινου του δερματος, χρησιμοποιωντας συνθεσεις οι οποιες περιλαμβανουν εναν αναστολεα του υποδοχεα ενδοθηλινης β
ATE308610T1 (de) Dreidimensionales hautmodell
DE50107180D1 (de) Haartonikum zur Vorbeugung oder Behandlung von Haarausfall
BR9507112A (pt) Preparações higiênicas e cosméticas para evitar e tratar doenças de pele processo para obtenção das mesmas e uso de água esgotada de deutério
ATE56862T1 (de) Hautbehandlungszusammensetzung.
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE281167T1 (de) Verwendung von makroliden zur behandlung von trockenen augen
DE3376524D1 (en) Skin treatment composition
WO2002064088A3 (en) Pharmaceutical composition for the treatment of alopecia
ATE514771T1 (de) Haartransplantation
ATE218862T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
ES2137125A1 (es) La utilizacion de la sal de zinc del acido glicirretico en preparados contra el acne y las composiciones que contienen dicha sal.
ID24060A (id) Pengolahan kulit hewan yang ditingkatkan
TW200716979A (en) Screening methods for compounds that affect melanogenesis
DK1115375T3 (da) Anvendelse af mindst ét 10-hydroxy-2-decensyrederivat i et præparat til at fremme hudafstödning
DE69820911D1 (de) Verwendung einer Verbindung zur Herstellung eines Medikaments zur Behandlung von Alopecia oder zur Förderung des Haarwuchses bei Tieren
HUP9900007A2 (hu) Készítmény baromfialom kezelésére
ATE358490T1 (de) Verwendung einer kombination aus einem purin und einem no-donor zur behandlung und prophylaxe sexueller funktionsstörungen
ES2152187A1 (es) Locion estimulante del foliculo piloso.
FI965171L (fi) Oksatsofosforiinien, esimerkiksi ifosfamidin, enantiomeerien käyttö kasvainten hoidossa sivuvaikutuksien vähentämiseksi